CHAPTER 129 – REFERENCES 1. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis 33. Kalia J, Swartz KJ. Elucidating the molecular basis of action of a classic drug: and treatment. Mayo Clin Proc 2010;85:838–854. guanidine compounds as inhibitors of voltage-gated potassium channels. 2. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous sys- Mol Pharmacol 2011;80:1085–1095. tem. N Engl J Med 2003;349:1543–1554. 34. Sanders DB, Massey JM, Sanders LL, et al. A randomized trial of 3. Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J 3,4- diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology Rare Dis 2007;2:22. 2000;54:603–607. 4. de Beukelaar JW, Sillevis Smitt PA. Managing paraneoplastic neurological 35. McEvoy KM, Windebank AJ, Daube JR, et al. 3,4-Diaminopyridine in the disorders. Oncologist 2006;11:292–305. treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989;321: 5. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies 1567–1571. to synaptic and neuronal cell surface proteins. Neurology 2011;77:179–189. 36. Low PA. Autonomic neuropathies. Curr Opin Neurol 2002;15:605–609. 6. Albert ML, Austin LM, Darnell RB. Detection and treatment of activated 37. Gupta V, Lipsitz LA. Orthostatic hypotension in the elderly: diagnosis and T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar treatment. Am J Med 2007;120:841–847. degeneration. Ann Neurol 2000;47:9–17. 38. Calvet X, Martinez JM, Martinez M. Repeated neostigmine dosage as pal- 7. Antoine JC, Camdessanche JP. Treatment options in paraneoplastic dis- liative treatment for chronic colonic pseudo-obstruction in a patient with orders of the peripheral nervous system. Curr Treat Options Neurol 2013; autonomic paraneoplastic neuropathy. Am J Gastroenterol 2003;98:708–709. 15:210–223. 39. Graus F, Dalmou J, Rene R, et al. Anti-Hu antibodies in patients with small- 8. Psimaras D, Carpentier AF, Rossi C, et al. Cerebrospinal fluid study in para- cell lung cancer: association with complete response to therapy and im- neoplastic syndromes. J Neurol Neurosurg Psychiatry 2010;81:42–45. proved survival. J Clin Oncol 1997;15:2866–2872. 9. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria 40. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2006;69:2124–2130. 2004;75:1135–1140. 41. Lehrich RW, Ortiz-Melo DI, Patel MB, et al. Role of vaptans in the manage- 10. Kannoth S. Paraneoplastic neurologic syndrome: A practical approach. Ann ment of hyponatremia. Am J Kidney Dis 2013;62:364–376. Indian Acad Neurol 2012;15:6–12. 42. Raftopoulos H. Diagnosis and management of hyponatremia in cancer pa- 11. Wright CE, Angus JA. Effects of N-, P- and Q-type neuronal calcium chan- tients. Support Care Cancer 2007;15:1341–1347. nel antagonists on mammalian peripheral neurotransmission. Br J Pharmacol 43. List AF, Hainsworth JD, Davis BW, et al. The syndrome of inappropriate 1996;119:49–56. secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin 12. Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium Oncol 1986;4:1191–1198. channels. Physiol Rev 2003;83:117–161. 44. Talmi YP, Hoffman HT, McCabe BF. Syndrome of inappropriate secretion 13. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in of arginine vasopressin in patients with cancer of the head and neck. Ann the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Otol Rhinol Laryngol 1992;101:946–949. Med 1995;332:1467–1474. 45. Ferlito A, Rinaldo A, Devaney KO. Syndrome of inappropriate antidiuretic 14. Bernal F, Shams’ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneo- hormone secretion associated with head neck cancers: review of the litera- plastic cerebellar degeneration and Hodgkin’s disease. Neurology 2003;60: ture. Ann Otol Rhinol Laryngol 1997;106:878–883. 230–234. 46. Lee BW, Ihm SH, Shin HS, et al. Malignant thymoma associated with myas- 15. Linke R, Schroeder M, Helmberger T, et al. Antibody-positive paraneoplastic thenia gravis, Graves’ disease, and SIADH. Intern Med 2008;47:1009–1012. neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 47. Galesic K, Krizanac S, Vrkljan M, et al. Syndrome of inappropriate secre- 2004;63:282–286. tion of antidiuretic hormone due to malignant thymoma. Nephron 2002;91: 16. Shams’ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degen- 752–754. eration associated with antineuronal antibodies: analysis of 50 patients. Brain 48. Eliakim R, Vertman E, Shinhar E. Syndrome of inappropriate secretion of 2003;126:1409–1418. antidiuretic hormone in Hodgkin’s disease. Am J Med Sci 1986;291:126–127. 17. Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic 49. Kobayashi K, Yokote T, Akioka T, et al. Inappropriate antidiuretic hormone cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain production in diffuse large B-cell lymphoma. Br J Haematol 2008;143:2. 1997;120:1279–1300. 50. Hirata Y, Yokote T, Nishiwaki U, et al. Syndrome of inappropriate antidi- 18. Bataller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic uretic hormone secretion associated with primary cutaneous anaplastic large or paraneoplastic opsoclonus-myoclonus. Brain 2001;124:437–443. cell lymphoma. Br J Haematol 2012;157:412. 19. Hassan KA, Kalemkerian GP, Trobe JD. Long-term survival in paraneoplas- 51. Nagashima Y, Iino K, Oki Y, et al. A rare case of ectopic antidiuretic hor- tic opsoclonus-myoclonus syndrome associated with small cell lung cancer. mone-producing pancreatic adenocarcinoma: new diagnostic approach. In- J Neuroophthalmol 2008;28:27–30. tern Med 1996;35:280–284. 20. DiBaise JK. Paraneoplastic gastrointestinal dysmotility: when to consider and 52. Garzotto M, Beer TM. Syndrome of inappropriate antidiuretic hormone se- how to diagnose. Gastroenterol Clin North Am 2011;40:777–786. cretion: a rare complication of prostate cancer. J Urol 2001;166:1386. 21. Lennon VA, Sas DF, Busk MF, et al. Enteric neuronal autoantibodies in pseu- 53. Yamazaki T, Suzuki H, Tobe T, et al. Prostate adenocarcinoma producing doobstruction with small-cell lung carcinoma. Gastroenterology 1991;100: syndrome of inappropriate secretion of antidiuretic hormone. Int J Urol 137–142. 2001;8:513–516. 22. Lee HR, Lennon VA, Camilleri M, et al. Paraneoplastic gastrointestinal mo- 54. Gasparini ME, Broderick GA, Narayan P. The syndrome of inappropriate tor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol antidiuretic hormone secretion in a patient with adenocarcinoma of the pros- 2001;96:373–379. tate. J Urol 1993;150:978–980. 23. Zisimopoulou P, Brenner T, Trakas N, et al. Serological diagnostics in myas- 55. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342: thenia gravis based on novel assays and recently identified antigens.Autoim- 1581–1589. mun Rev 2013;12:924–930. 56. Arieff AI, Llach F, Massry SG. Neurological manifestations and morbidity 24. Evoli A, Minisci C, Di Schino C, et al. Thymoma in patients with MG: of hyponatremia: correlation with brain water and electrolytes. Medicine characteristics and long-term outcome. Neurology 2002;59:1844–1850. 1976;55:121–129. 25. Rosenberg M, Jauregui WO, De Vega ME, et al. Recurrence of thymic hy- 57. Gross P, Reimann D, Neidel J, et al. The treatment of severe hyponatremia. perplasia after thymectomy in myasthenia gravis. Its importance as a cause of Kidney Int Suppl 1998;64:S6–S11. failure of surgical treatment. Am J Med 1983;74:78–82. 58. Gullans SR, Verbalis JG. Control of brain volume during hyperosmolar and 26. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic hypoosmolar conditions. Ann Rev Med 1993;44:289–301. factors for long-term outcome in patients with anti-NMDA receptor enceph- 59. Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatre- alitis: an observational cohort study. Lancet Neurol 2013;12:157–165. mia is associated with falls, unsteadiness, and attention deficits.Am J Med 27. Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle 2006;119:71.e1–e8. weakness between myasthenia gravis and the Lambert-Eaton myasthenic syn- 60. Schwartz WB, Bennett W, Curelop S, et al. A syndrome of renal sodium loss drome. J Neurol Neurosurg Psychiatry 2002;73:766–768. and hyponatremia probably resulting from inappropriate secretion of antidi- 28. Oh SJ, Kurokawa K, Claussen GC, et al. Electrophysiological diagnostic crite- uretic hormone. Am J Med 1957;23:529–542. ria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005;32:515–520. 61. Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of an- 29. Voltz R. Intravenous immunoglobulin therapy in paraneoplastic neurologi- tidiuretic hormone. Am J Med 1967;42:790–806. cal syndromes. J Neurol 2006;253:V33–V38. 62. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidi- 30. Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) uresis. N Engl J Med 2007;356:2064–2072. adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol 63. Feldman BJ, Rosenthal SM, Vargas GA, et al. Nephrogenic syndrome of in- Oncol 2006;28:585–593. appropriate antidiuresis. N Engl J Med 2005;352:1884–1890. 31. Shams’ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of ritux- 64. Decaux G, Brimioulle S, Genette F, et al. Treatment of the syndrome of imab for antibody associated paraneoplastic neurological syndromes. J Neu- inappropriate secretion of antidiuretic hormone by urea. Am J Med 1980;69: rol 2006;253:16–20. 99–106. 32. Punga AR, Stalberg E.